Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 5 versus AMINOSYN II 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 5 versus AMINOSYN II 8 5 W ELECTROLYTES.
AMINOSYN II 5% vs AMINOSYN II 8.5% W/ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 5% provides essential and non-essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair. It supports metabolic processes in patients unable to maintain adequate nutrition enterally.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
Intravenous infusion via central line, initial rate 50 mL/hour, increase by 25 mL/hour every 24 hours to goal rate of 1-2 mL/kg/hour (maximum 125 mL/hour). Total daily dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 30-40 mL/kg/day).
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
None Documented
None Documented
Not applicable as a single entity; individual amino acids have variable half-lives (e.g., 10-30 min for most), reflecting rapid distribution and metabolism. Clinical context: continuous infusion maintains steady state.
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
Renal elimination of amino acids is minimal under normal conditions; excess amino acids are metabolized, and nitrogen is excreted as urea (renal, ~80-90%) and ammonia. Biliary/fecal excretion negligible.
Renal >90% (as amino acids and metabolites); fecal <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution